Zacks Investment Research lowered shares of Chimerix, Inc. (NASDAQ:CMRX) from a buy rating to a hold rating in a report published on Thursday.

According to Zacks, “Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina. “

Separately, FBR & Co reissued a hold rating on shares of Chimerix in a report on Sunday, October 30th. One analyst has rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average price target of $7.70.

Chimerix (NASDAQ:CMRX) traded up 0.34% during trading on Thursday, hitting $5.99. 130,359 shares of the company were exchanged. Chimerix has a 12 month low of $3.49 and a 12 month high of $7.84. The company’s market capitalization is $277.43 million. The stock’s 50-day moving average is $5.18 and its 200-day moving average is $4.88.

“Chimerix, Inc. (CMRX) Downgraded by Zacks Investment Research to “Hold”” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was copied illegally and republished in violation of international copyright and trademark laws. The original version of this piece can be accessed at http://www.watchlistnews.com/chimerix-inc-cmrx-downgraded-by-zacks-investment-research-to-hold/1120666.html.

In other Chimerix news, Director Ernest Mario sold 100,000 shares of the stock in a transaction dated Wednesday, December 28th. The shares were sold at an average price of $4.64, for a total transaction of $464,000.00. Following the completion of the transaction, the director now owns 12,905 shares of the company’s stock, valued at $59,879.20. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 10.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Chimerix by 1,146.3% in the third quarter. JPMorgan Chase & Co. now owns 545,574 shares of the biopharmaceutical company’s stock valued at $3,022,000 after buying an additional 501,800 shares during the period. Baker BROS. Advisors LP bought a new position in shares of Chimerix during the third quarter valued at $638,000. Los Angeles Capital Management & Equity Research Inc. raised its position in shares of Chimerix by 30.6% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 107,005 shares of the biopharmaceutical company’s stock valued at $593,000 after buying an additional 25,060 shares during the period. Shell Asset Management Co. bought a new position in shares of Chimerix during the third quarter valued at $623,000. Finally, Highbridge Capital Management LLC raised its position in shares of Chimerix by 506.8% in the third quarter. Highbridge Capital Management LLC now owns 173,888 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 145,232 shares during the period. 68.66% of the stock is owned by institutional investors.

About Chimerix

Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.

5 Day Chart for NASDAQ:CMRX

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.